Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Sosei Group Corporation ("the Company"; TSE: 4565) today announced it has received grant funding from Wellcome, through the COVID-19 Therapeutics...
Sosei Group Corporation ("the Company") (TSE: 4565) notes that in AstraZeneca's third quarter 2021 clinical trials appendix presentation (published...
Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities during the third quarter 2021 and reports its...
Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
Sosei Group Corporation ("the Company") (TSE: 4565), the world leader in GPCR-focused structure-based drug design and development, and InveniAI® LLC...
Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1...
Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new...
Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...
Sosei Group Corporation ("the Company") (TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has dosed the first patient in a...
Sosei Group Corporation ("the Company") (TSE: 4565) notes the announcement today from Centessa Pharmaceuticals ("Centessa") about its launch as a...
Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12...
Sosei Group Corporation ("the Company"; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and...
Sosei Group Corporation ("the Company") (TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply ...
Sosei Group Corporation ("the Company";) (TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 39th Annual J.P....
Sosei Group Corporation ("the Company") (TSE: 4565) announces it is to regain the worldwide rights to its muscarinic agonist programs. The program...
Sosei Group Corporation ("the Company") (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor...
Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with GlaxoSmithKline...
Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven...
Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel...
Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the nine...
Sosei Group Corporation ("the Company") (TSE: 4565) has entered into an agreement1 with Tempero Bio, under which Tempero Bio has in-licensed...
Sosei Group Corporation ("the Company") (TSE: 4565) today announces the appointment of Hironoshin Nomura, as Senior Vice President Investor Relations ...
Sosei Group Corporation ("the Company") (TSE: 4565) today announces the successful completion of an International Offering of new shares and euro-yen ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.